Wisconsin Breast Cancer Showhouse
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

  • Home
  • About Us
  • events
  • Research
    • Breast Cancer Research
    • Prostate Cancer Research
    • Current Research
  • Contact Us
  • Donate Now
  • Donors
  • More
    • Home
    • About Us
    • events
    • Research
      • Breast Cancer Research
      • Prostate Cancer Research
      • Current Research
    • Contact Us
    • Donate Now
    • Donors
Wisconsin Breast Cancer Showhouse

Signed in as:

filler@godaddy.com

  • Home
  • About Us
  • events
  • Research
    • Breast Cancer Research
    • Prostate Cancer Research
    • Current Research
  • Contact Us
  • Donate Now
  • Donors

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

CURRENT RESEARCH

Yunguang Sun, MD, PhD, Assistant Professor, Pathology & Laboratory Medicine, Medical College of WI.

 Research Title: “New therapeutic approaches to estrogen receptor-positive breast cancer

Eighty percent of newly diagnosed breast cancer cases are Estrogen

receptor-positive (ER+). More than twenty percent of these patients

are projected to die despite anti-estrogen therapy. Currently a lack

of effective preclinical models of human Estrogen receptor-positive

breast cancer has hampered efforts to find better treatments. Our

goal is to develop better human tumor models to test new drugs and

    treatment options. In our work thus far, we revealed DNA repair pathway

deficiencies in our aggressive patient-derived Luminal B tumor models

that could lead to more targeted therapy. Our expectation is that further

study will yield insights that can be rapidly adapted to clinical trials for

patients with Estrogen receptor-positive breast cancer of the aggressive

Luminal B subtype.

Carol L. Williams, PhD, Joan K. Van Deuren Professor in Breast Cancer Research,

 Professor, Pharmacology & Toxicology, Medical College of Wisconsin 

 

 Research Title: “A novel strategy to suppress the activity of oncogenic small GTPases in breast cancer” 


 Breast cancer remains a leading killer of women, and our researchis aimed at developing better treatments for breast cancer. We areidentifying new therapeutic targets that promote breast cancer anddeveloping drugs that inhibit their cancer-causing properties. Wediscovered that SmgGDS helps breast cancer cells form tumors byactivating a group of tumor-promoting proteins called small GTPases.


Our goal is to stop breast cancer cells from using SmgGDS to formtumors. We have developed a promising compound called a spliceswitchingoligonucleotide (SSO) that alters the production of SmgGDSin breast cancer cells. We are exploring the use of this SSO compoundas a new strategy to treat breast cancer. 

Marja Nevalainen MD, PhD, Professor, Eminent Scholar, Dept. of Pathology and

Pharmacology & Toxicology

 

Research Title: “Stat5 and Anti-Androgen-Induced Metastatic Phenotype of Prostate Cancer”


Treatment options for metastatic prostate cancer (MPC) are

limited to androgen-deprivation-therapy. The new-generation antiandrogen, Enzalutamide dominates the clinical space and is FDA

approved in pre- and post-chemotherapy settings. Resistance to

Enzalutamide arises within 3-6 months, with patients developing terminal

castrate-resistant (CR)-MPC. There are no effective therapies for CR-MPC.

Our data support a novel concept that Stat5 promotes development of

Enzalutamide-resistant prostate cancer (ERPC). We previously showed

that Stat5 induces metastatic behavior of PC cells. Also, Enzalutamide

has been shown to induce metastatic phenotype of PC. Our new data

show that Enzalutamide induces Jak2-Stat5 activation in PC. This proposal

will test whether Enzalutamide induction of Jak2-Stat5 signaling in PC

mediates Enzalutamide promotion of CR-MPC and may result in a new

therapeutic strategy for ERPC by exploiting Jak2-Stat5 pathway inhibitors

that are in clinical development for leukemias. Our goal is that this project

results in development of a new therapy for ERPC.

The WBCS Scientific Review Committee

Each year, our Scientific Review Committee evaluates proposals from researchers at the Medical College of Wisconsin (MCW) to choose the most promising studies that are aligned with the mission of WBCS. We play an active role as a partner of MCW. 

Learn more

Copyright © 2025 Wisconsin Breast Cancer Showhouse - All Rights Reserved.

Powered by